Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

New England Journal of Medicine, Journal Year: 2020, Volume and Issue: 383(23), P. 2207 - 2218

Published: Dec. 2, 2020

Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 as compared with chemotherapy first-line therapy for MSI-H–dMMR advanced metastatic colorectal cancer is unknown.

Language: Английский

---

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Journal of Clinical Oncology, Journal Year: 2018, Volume and Issue: 36(8), P. 773 - 779

Published: Jan. 20, 2018

Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the cohort of CheckMate-142, largest single-study report an immunotherapy combination dMMR/MSI-H mCRC, are reported. Patients Methods received 3 mg/kg 1 once every weeks (four doses) followed by 2 weeks. Primary end point was investigator-assessed ORR. Results Of 119 patients, 76% had ≥ two prior systemic therapies. At median follow-up 13.4 months, ORR 55% (95% 45.2 63.8), 12 80%. Median duration not reached; most responses (94%) were ongoing at data cutoff. Progression-free rates (9 months) 71% (12 months); respective OS 87% 85%. Statistically significant clinically meaningful improvements observed patient-reported outcomes, including functioning, symptoms, quality life. Grade 4 treatment-related adverse events (AEs) occurred 32% manageable. (13%) who discontinued treatment because study drug-related AEs (63%) consistent that population. Conclusion demonstrated high rates, encouraging progression-free manageable safety, key Indirect comparisons suggest therapy improved efficacy relative anti-programmed death-1 monotherapy has a favorable benefit-risk profile. promising new option mCRC.

Language: Английский

---

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology, Journal Year: 2017, Volume and Issue: 28, P. iv22 - iv40

Published: May 5, 2017

Language: Английский

---

Comprehensive review of targeted therapy for colorectal cancer

Signal Transduction and Targeted Therapy, Journal Year: 2020, Volume and Issue: 5(1)

Published: March 20, 2020

Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in world was responsible for nearly 881,000 cancer-related deaths 2018. Surgery chemotherapy have long been first choices patients. However, prognosis of CRC has never satisfying, especially patients with metastatic lesions. Targeted therapy a new optional approach that successfully prolonged overall survival Following successes anti-EGFR (epidermal growth factor receptor) agent cetuximab anti-angiogenesis bevacizumab, agents blocking different critical pathways as well immune checkpoints are emerging at an unprecedented rate. Guidelines worldwide currently updating recommended targeted drugs on basis increasing number high-quality clinical trials. This review provides overview existing CRC-targeted their underlying mechanisms, discussion limitations future trends.

Language: Английский

---

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, Journal Year: 2021, Volume and Issue: 19(3), P. 329 - 359

Published: March 1, 2021

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer focuses on systemic therapy options treatment of metastatic colorectal cancer (mCRC), because important updates have recently been made to this section. These include recommendations first-line use checkpoint inhibitors mCRC, that is deficient mismatch repair/microsatellite instability-high, related biosimilars, and expanded biomarker testing. The now targeted patients with mCRC HER2-amplified, or BRAF V600E mutation–positive. Treatment management nonmetastatic resectable/ablatable disease are discussed complete version available at NCCN.org . Additional topics covered risk assessment, staging, pathology, posttreatment surveillance, survivorship.

Language: Английский

---

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology, Journal Year: 2022, Volume and Issue: 34(1), P. 10 - 32

Published: Oct. 25, 2022

Language: Английский

---

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

Cancer Treatment Reviews, Journal Year: 2020, Volume and Issue: 86, P. 102017 - 102017

Published: March 26, 2020

When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of first targeted therapies and approved angiogenesis inhibitor. Marking beginning for a new line anti-cancer treatments, remains most extensively characterized anti-angiogenetic treatment. Initially treatment metastatic colorectal cancer in combination with chemotherapy, its indications now include breast cancer, non-small-cell lung glioblastoma, renal cell carcinoma, ovarian cervical cancer. This review provides an overview experience lessons learned since bevacizumab's initial approval, highlights how this knowledge has led to investigation novel therapies. In past years, our understanding VEGF's role tumor microenvironment evolved. We know that VEGF not only plays major controlling blood vessel formation, but also modulates tumor-induced immunosuppression. These immunomodulatory properties have opened up perspectives therapy approaches, which are being investigated trials. Specifically, immunotherapy recently been benefit demonstrated hepatocellular carcinoma. However, despite intense investigation, reliable validated biomarkers would enable personalized use remain elusive. Overall, is expected key agent therapy, both due established efficacy promise as partner treatments.

Language: Английский

---

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

Annals of Oncology, Journal Year: 2017, Volume and Issue: 28(8), P. 1713 - 1729

Published: April 5, 2017

Language: Английский

---

5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future

Pharmacology & Therapeutics, Journal Year: 2019, Volume and Issue: 206, P. 107447 - 107447

Published: Nov. 19, 2019

Language: Английский

---

Colorectal cancer liver metastases – a population-based study on incidence, management and survival

BMC Cancer, Journal Year: 2018, Volume and Issue: 18(1)

Published: Jan. 15, 2018

Colorectal cancer (CRC) is a leading cause of cancer-associated deaths with liver metastases developing in 25-30% those affected. Previous data suggest survival difference between right- and left-sided metastatic CRC, even though has higher incidence metastases. The aim the study was to describe patterns as function characteristics primary tumour different combinations disease.A retrospective population-based performed on cohort patients diagnosed CRC region Stockholm, Sweden during 2008. Patients were identified through Swedish National Quality Registry for Cancer Treatment (SCRCR) additional information intra- extra-hepatic pattern treatment retrieved from electronic patient records. followed 5 years or until death. Factors influencing overall (OS) investigated by means Cox regression. OS compared using Kaplan-Meier estimations log-rank test.Liver 272/1026 (26.5%) within five diagnosis primary. Liver lung more often colon right-sided (28.4% versus 22.1%, p = 0.029 19.7% 13.2%, 0.010, respectively) but extent extensive (p 0.001). cancer, including rectal associated 44% decreased mortality risk (HR 0.56, 95% CI: 0.39-0.79) 5-year 16.6% 4.3% < In presence did not significantly influence assessed multivariate analysis 1.11, 0.80-1.53).The worse could possibly be explained number metastases, well segmental involvement latter had Detailed assist structured individualized guidelines follow-up CRC.

Language: Английский

---